Randomized Phase 2 Study of Gemcitabine/Cisplatin With or Without SAR240550 (BSI-201), a PARP1 Inhibitor, in Patients With Stage IV Non-small Cell Lung Cancer.

Trial Profile

Randomized Phase 2 Study of Gemcitabine/Cisplatin With or Without SAR240550 (BSI-201), a PARP1 Inhibitor, in Patients With Stage IV Non-small Cell Lung Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Aug 2014

At a glance

  • Drugs Iniparib (Primary) ; Cisplatin; Gemcitabine
  • Indications Non-small cell lung cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 24 Mar 2012 This trial is recruiting in France and England.
    • 03 Nov 2011 Status changed from active, no longer recruiting to completed. Initial study results presented at the 2011 European Multidisciplinary Cancer Congress.
    • 27 Sep 2011 Initial tolerability results presented at the 2011 European Multidisciplinary Cancer Congress, final efficacy and safety data to follow.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top